Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The recent release of the joint ASCO/AUA guideline on chemoprevention of prostate cancer with 5-ARIs has necessitated several updates to the web site, including significant modifications to: The main Risk and Prevention page The page on Finasteride and the Prostate Cancer Prevention Trial
Filed under: Uncategorized | Comments Off
Looking through my assorted notes from the meeting this morning after getting home late last night, there are four other poster presentations that are worth commenting on very specifically, and then a general comment that I would add.
Filed under: Management, Treatment | Tagged: abiraterone, active surveillance, anxiety, cost, depression, MDV3100, radical prostatectomy | Leave a Comment »
During the oral sessions on prostate cancer management yesterday, there were two topics that generated significant differences of opinion between presenters: the relative benefits of salvage vs. adjuvant radiotherapy in men post-surgery and whether focal therapy (whether executed with HIFU or cryotherapy or any other means) is actually a valid from of treatment.
Filed under: Management, Treatment, Uncategorized | Tagged: adjuvant radiation, focal therapy, salvage radiation | 3 Comments »
In news from sources other than the Genitourinary Cancer Symposium today, we have six reports on: Oxidative stress and the development of prostate cancer A review of PSA kinetics in the diagnosis, prognosis, and monitoring of prstate cancer Focal therapy in general and focal cryoablation specifically The relevance of elevated chondroitin sulphate levels and androgen [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: androgen receptor, chondroitin sulphate, cryoablation, focal therapy, oxidative stress, PSA kinetics | Leave a Comment »
Today was “prostate cancer day” at the annual Genitourinary Cancer Symposium in Orlando, Florida. I had hoped to be able to blog from the actual sessions, but unfortunately there was no wireless access from within the main meeting room. However …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Comments Off
There are few published reports on changes in continence and erectile function beyond 2 years after radical prostatectomy. A newly published, prospective study has reported on continence and erectile function between 2 and 4 years after radical prostatectomy.
Filed under: Living with Prostate Cancer | Tagged: erectile function, incontinence, post-surgery | Leave a Comment »
Our third report today covers such topics as: A positive biopsy risk nomogram for men in New Zealand A review of current trends and priorities in surgical technique for radical prostatectomy A review of the potential of functional MRI-based systems for the diagnosis of prostate cancer Demonstration of a relationship between circulating tumor cells and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biopsy, blood, circulating tumor cells, CTCs, Diagnosis, DNA, functional, IMRT, MRI, New Zealand, nomogram, radical prostatectomy, risk, technique, treatment planning | Leave a Comment »
Our second report today deals with: Soy isoflavone concentration in prostate cancer tissue A new vitamin E ether analog and its activity in the laboratory PSA “half-life” as a prognostic indicator for impact of hormone therapy Apolipoprotein C-I: is it important hormone-refractory prostate cancer? Chemotherapeutic sensitization and its possible impact on taxane therapy
Filed under: Uncategorized, Prevention, Diagnosis, Living with Prostate Cancer, Drugs in development, Risk | Tagged: chemotherapy, prognosis, soy, isoflavone, vitamin E analog, VEBSA, PSA "half-life", apolipoprotein, sensitization, taxane | Leave a Comment »
There has been a positive plethora of news reports over the past 24 hours, starting with the very important issuance of the AUA/ASCO guideline on the potential use of 5-ARIs for the prevention of prostate cancer. This will be just the first of at least three groups of news reports today! This report deals with: [...]
Filed under: Diagnosis, Drugs in development, Risk | Tagged: ethnicity, IGF-I, insulin-like growth factor I, phenoxodiol, PSA, race, sarcosine research test, variants | Leave a Comment »
The “New” Prostate Cancer InfoLink is delighted to report that a joint ASCO/AUA task force has just issued a new set of guidelines recommending discussion between doctors and their patients about the potential use of 5α-reductase inhibitors (5-ARIs) such as finasteride or dutasteride as agents to reduce the risk of prostate cancer.
Filed under: Prevention | Tagged: 5-ARI, 5α-reductase inhibitors, dutasteride, finasteride, Prevention | Leave a Comment »
Park et al. have just reported the results of the truly vast NIH-AARP Diet and Health Study, which included data from more than 490,000 older men and women (aged between 50 and 71 when the study started in the 1990s) over an average 7-year follow-up period.
Filed under: Prevention | Tagged: calcium, diet, health, Prevention, risk | Leave a Comment »
There’s a nice little article on Gather.com today by Marc Garnick, MD dealing with current knowledge about the use of supplements in prevention of prostate cancer. Dr. Garnick knows a little about prostate cancer. (He was heavily involved in the development of leuprolide acetate and of the first LHRH antagonist, abarelix.)
Filed under: Prevention, Uncategorized | Comments Off
We have dealt separately with an article on the way in which surgical technique appears to affect the likelihood of positive surgical margins after robot-assisted laparoscopic prostatectomy (RALP). Other reports today cover: Whether multifocal tumors are “riskier” that single prostate cancer tumors The role of n-3 fatty acids in prevention of selected cancers (including prostate [...]
Filed under: Management, Prevention, Risk, Treatment, Uncategorized | Tagged: carboplatin, cholesterol, etopside, localization, lycopene, multifocal, n-3 fatty acids, unifocal | Leave a Comment »
The apex of the prostate (the tip end of organ, farthest from the bladder) is the most common site in which positive surgical margins seem to be found after robot-assisted laparoscopic prostatectomy (RALP).
Filed under: Management, Treatment | Tagged: positive surgical margin, RALP, surgical technique | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site